Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value Peer-spectives
Filter by Topic
ASCO’s Value Framework
Commentary
Employers’ Perspective
Letter to our Readers
Oncologist–Patient Communication
Patient Communication
Patient Perspective
Payer’s Perspective
Practice Management
Testimonials
The Patient Perspective
Value in Oncology
Value Propositions
VBCC Perspectives
Telehealth Applications in Patient Care
By
F. Randy Vogenberg, PhD, RPh, FASHP
Employers’ Perspective
,
Value Peer-spectives
June 2016, Vol 7, No 5
The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using some form of medical technology, whereas telehealth has a much broader definition that comprises education, disease awareness, and wellness, in addition to the use of technology to connect physicians to patients.
Read Article
Oncology Biosimilars: Opportunity or Not?
By
Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA
;
F. Randy Vogenberg, PhD, RPh, FASHP
Employers’ Perspective
,
Value Peer-spectives
,
Biosimilars
April 2016, Vol 7, No 3
The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and growth factors. Cancer treatments utilize traditional chemical-based drugs and, increasingly, biologic-based drugs.
Read Article
Value-Based Care Must Be Linked to Improved Clinical Outcomes
By
James T. Kenney, RPh, MBA
Economics & Value
,
Payer’s Perspective
,
Value-Based Care
,
Value Peer-spectives
February 2016, Vol 7, No 1
Society meetings, such as the recent American Society of Hematology (ASH) annual meeting, generate a lot of clinical-related excitement regarding new treatment options, protocols, and pathways for hematologic cancers.
Read Article
Big Data in Cancer Care: Limitations of Drug Claims
By
Catherine E. Cooke, PharmD, BCPS
;
F. Randy Vogenberg, PhD, RPh, FASHP
Cancer Care
,
Employers’ Perspective
,
Value Peer-spectives
March 2016, Vol 7, No 2
As one part of an ongoing macrotheme regarding big data, understanding the benefits and limitations of using drug claims in employer-based population health is an important topic for employers in their health plan coverage strategies. Pharmacy claims are a common source of data used to describe the uses of cancer medications by employees and by their covered family members. Despite the availability of these data and a plethora of analyses, however, several limitations must be considered when interpreting drug use data.
Read Article
Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
By
Wayne Kuznar
Value Propositions
,
Value Peer-spectives
October 2015, Vol 6, No 9
Washington, DC—Complex partnerships among cancer care stakeholders, including drug manufacturers, are becoming the norm.
Read Article
Breaking Bad News to Patients with Cancer: Oncologists’ Emotional Burden and Need for Support Systems
By
Mary Mosley
Oncologist–Patient Communication
,
Value Peer-spectives
October 2015, Vol 6, No 9
Much attention is given to how bad news affects patients with cancer. Yet, little is known about the experience of physicians and what is required by them to deliver this news.
Read Article
My Struggle to Understand the Many Definitions of Value
By
Burt Zweigenhaft, PhD, D.Litt
From the Editor
,
Value Peer-spectives
September 2015, Vol 6, No 8
I believe that the dialogue and thoughts being shared and expressed by all cancer care stakeholders is exactly what we need today. Frankly, the conversation has been underground far too long, but the headlines today have been focused solely on the drug cost. Anyone thinking that cancer care costs are going to go down, simply doesn’t understand healthcare economics, because the cost to society will continue to go up over time, with true innovation and value delivered.
Read Article
Communication with Oncologists, Not Cost, Tops Patients’ Value Priorities
By
Chase Doyle
Oncologist–Patient Communication
,
Value in Oncology
,
Value Peer-spectives
September 2015, Vol 6, No 8
The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders.
Read Article
A Patient’s Perception of Value in Cancer Treatment Today
By
Marion Toby Koch
Patient Perspective
,
Value Peer-spectives
August 2015, Vol 6, No 7
Science and technology have taken us through a dynamic portal, transforming medicine into a business and cancer into an industry that is challenged by its clinical benefits, safety, and cost-effectiveness. We are now witnessing a change in oncology with the migration from doctor- to patient-centric treatment.
Read Article
By Looking Back, We Learn to Look Forward
By
Burt Zweigenhaft, PhD, D.Litt
From the Editor
,
Value Peer-spectives
August 2015, Vol 6, No 7
My personal journey to understanding and experiencing up close and personal the complexities in cancer care started some 20 years ago, when, like many of us, someone extremely close to you gets the dreaded news, “you have cancer.” For me, this was my mom. Regretfully, as we grow older, we all continue to hear this dreadful tale more frequently. These events have transformed my career over time to turn it into a mission—improving cancer care and seeking the cure.
Read Article
Page 2 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma